It is well established that the frequency of AR amplification increases as prostate cancer progresses, with reported rates ranging from 10% to 20% in castration‐resistant prostate cancer (CRPC) and 41%–52% in mCRPC [15, 16, 17, 18, 19, 20]. This evidence concerns the gene AR and prostate carcinoma.